Members: 2116 Newest Member: Ste Members | JOIN Search Pills Downloads Articles Links News Pictures

Pills Menu Home Articles Forum Links Podcast Downloads Pictures Polls Help-FAQ Contacts Tag Cloud Search Site Site Map care resources Sign in Register Members
Members: 2116 Newest Member: Ste Members | JOIN Search Pills Downloads Articles Links News Pictures Comments regional PPIs are all equal? Submitted August 11, 2006 by admin. - Clinical_queries - reports to:
Proton Pump Inhibitors are all equal in gastroduodenal diseases? Key questions: 1. Is there different efficacy between various PPI in adult patients with symptoms of GERD? 2. Is there a different between the various PPI effectiveness in adult patients with Peptic Ulcer and NSAID-induced ulcer? 3. Is there a difference in the safety data sheet / compliance among various polycystic kidney disease PPI in adult patients treated for symptoms of GERD, Ulcer Peptic ulcer or NSAID-induced? 4. There are differences between PPI within subgroups of populations on the basis of demographics, drug interactions or comorbidit? Efficacy and safety profile of PPIs in GERD Healing. Eight comparative studies and a systematic review found no differences between omeprazole, lansoprazole, rabeprazole and pantoprazole at 4 and 8 weeks. A trial with esomeprazole 40 mg versus lansoprazole 30 mg has found a better efficiency in the esomeprazole group with an NNT of 29. Symptoms. Eight comparative studies found no significant differences in relieving symptoms of omeprazole, lansoprazole, rabeprazole and pantoprazole. Two studies found that esomeprazole 40 mg was better in relieving symptoms that omeprazole 20 mg. Prevention of relapse. Three RCTs they compared a PPI with another as maintenance therapy for prevention of esophagitis. Two of them did not find differences in the percentage of recurrent symptomatic or endoscopic between lansoprazole and omeprazole after 48 weeks or rabeprazole and omeprazole after 13, 26 and 52 weeks. The third comparing polycystic kidney disease esomeprazole 20 mg with lansoprazole 15 mg. After six months remained healed for 83% of esomeprazole to 74% of lansoprazole to 6 months. Many patients in the esomeprazole group remained healed in all degrees of severity and in the lansoprazole group effectiveness polycystic kidney disease decreased with increasing severity. The study, it must be said, could be flawed in favor of esomeprazole. Adverse polycystic kidney disease effects. In comparative studies there were no significant differences between the various PPI. Effectiveness of the various PPI in peptic ulcer and NSAID-induced ulcer Duodenal. The evidence is strong for Omeprazole and Lansoprazole that have similar efficacy in healing endoscopically and in relieving symptoms. The evidence for pantoprazole, rabeprazole and esomeprazole are less strong. No study found differences between PPI. Gastric ulcer. polycystic kidney disease There is only one comparative study between rabeprazole and omeprazole that has demonstrated no difference between the two PPI in the rate of healing. NSAID-induced ulcers. There are no comparative studies, so the power of the poor evidence. Prevention of NSAID-indorra. There are no comparative studies. Eradication polycystic kidney disease of Helicobacter Pylori. There are 16 comparative studies and a systematic review, but the significant heterogeneity between studies this greatly lowers the power of evidence. These studies found no significant differences between the various PPI. For other details polycystic kidney disease see a pill earlier on the same subject: http://www.pillole.org/public/aspnuke/news.asp?id=2257 Clementino Stefanetti Bibliography Drug Class Review on Proton Pump Inhibitors http: //www.ohsu. edu / drugeffectiveness / reports / documents / PPI% 20Final% polycystic kidney disease 20Report% 20Update% 203.pdf Systematic Review: polycystic kidney disease Comparative Direct Trials of the Efficacy of Proton Pump Inhibitors in the Management of Gastro-Oesophageal Reflux polycystic kidney disease Disease and Peptic Ulcer Disease. Aliment Pharmacol Ther 18 (6): 559-568, 2003. Views: 9649 | Back | | | | | ARCHIVE | SEARCH PILLS | LAST MONTH | THE MOST LETTE Add - Comments Comments flash before you must log in. For comments articulated use the Forum
22:28 hours | 15,178,446 accesses | Users Online: 450